 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...3435363738394041424344...208209» |
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: A single-arm trial of adebrelimab combined with induction chemotherapy and concurrent chemoradiotherapy in the treatment of locally advanced head and neck squamous cell carcinoma with CPS>=1 (EUDRACT) - Jun 5, 2025
P4, N=74, Recruiting, Sponsor: Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
- | Aidixi (disitamab vedotin) / Pfizer, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A randomised controlled study comparing adebelimab plus Disitamab Vedotin and carboplatin versus nab-paclitaxel plus carboplatin in the neoadjuvant treatment of HER2-low breast cancer (EUDRACT) - Jun 5, 2025
P2, N=72, Recruiting, Sponsor: Sun Yat-sen Memorial Hospital Sun Yat-sen University; Sun Yat-sen Memorial Hospital Sun Yat-sen University
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial, Real-world evidence: A Prospective/Retrospective Real-World Study of Adebrelimab in Extensive-Stage Small Cell Lung Cancer (EUDRACT) - Jun 5, 2025
P=N/A, N=500, Recruiting, Sponsor: Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Review, Journal: Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China. (Pubmed Central) - Jun 5, 2025
In general, the incidence of HER2-mutated NSCLC in the Chinese population seems to be higher than the world average, and there is a large number of missed HER2-mutated NSCLC patients in China. In this field, ADCs and novel TKIs are being developed and researched in spurts, and new drugs are moving from back-line therapy to front-line therapy, and from single-drug regimens to combination regimens.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Efficacy of transarterial chemoembolization-hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. (Pubmed Central) - Jun 5, 2025
In conclusion, TACE-HAIC combined with lenvatinib and camrelizumab significantly improved both OS and PFS times in patients with HCC and PVTT compared with TACE alone, despite a higher incidence of adverse events. This combination therapy represents a promising treatment strategy for this patient population, offering enhanced survival benefits.
- | Blincyto (blinatumomab) / Astellas, Amgen, Nailike (olverembatinib) / Takeda
Journal: Blinatumomab in combination with olverembatinib and concurrent intrathecal chemotherapy successfully treated a chronic myeloid leukemia relapse with central nervous system blast crisis: case report and literature review. (Pubmed Central) - Jun 5, 2025
This combination therapy represents a promising treatment strategy for this patient population, offering enhanced survival benefits. The combination of blinatumomab, olverembatinib, and concurrent intrathecal chemotherapy may be an effective treatment strategy for CML progression, particularly in cases with CNS involvement.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial (clinicaltrials.gov) - Jun 5, 2025
P2, N=30, Not yet recruiting, Sponsor: Jun Jia
- || Kailimei (satricabtagene autoleucel) / CARsgen
Enrollment closed, Trial primary completion date: CT041-ST-01: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection (clinicaltrials.gov) - Jun 5, 2025
P1/2, N=192, Active, not recruiting, Sponsor: CARsgen Therapeutics Co., Ltd.
The combination of blinatumomab, olverembatinib, and concurrent intrathecal chemotherapy may be an effective treatment strategy for CML progression, particularly in cases with CNS involvement. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2024 --> Oct 2024
- ||| HS-10502 / Jiangsu Hansoh Pharma
Enrollment open: HS-10502 Combination Treatment in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 4, 2025
P1, N=157, Recruiting, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2024 --> Oct 2024 Not yet recruiting --> Recruiting
- || remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Clinical, Journal: Effects of Remimazolam Tosilate Combined with Esketamine on Anesthetic Efficacy and Psychiatric Symptoms in Patients Undergoing Ambulatory Surgery: A Randomized Controlled Study. (Pubmed Central) - Jun 4, 2025
The SAS scores decreased from T2 to T4 in Groups EM and ER than in Group E (p<0.05). The combination of remimazolam tosilate and esketamine effectively reduces postoperative psychiatric symptoms, enhances hemodynamic stability, and improves recovery quality, making it a viable anesthetic strategy for ambulatory surgery.
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New trial: Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT (clinicaltrials.gov) - Jun 4, 2025
P=N/A, N=30, Enrolling by invitation, Sponsor: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
- | AiTan (rivoceranib) / HLB Bio Group, Lysodren (mitotane) / Perrigo Company
Trial completion date: Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma (clinicaltrials.gov) - Jun 3, 2025
P2, N=28, Recruiting, Sponsor: West China Hospital
The combination of remimazolam tosilate and esketamine effectively reduces postoperative psychiatric symptoms, enhances hemodynamic stability, and improves recovery quality, making it a viable anesthetic strategy for ambulatory surgery. Trial completion date: Dec 2030 --> Dec 2031
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
New P3 trial: EAST-LDL: Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion (clinicaltrials.gov) - Jun 2, 2025
P3, N=652, Not yet recruiting, Sponsor: Shanghai East Hospital
- || AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Enrollment open: Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma (clinicaltrials.gov) - Jun 2, 2025
P2, N=29, Recruiting, Sponsor: Sun Yat-sen University
Trial completion date: Dec 2030 --> Dec 2031 Not yet recruiting --> Recruiting
- | vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
Journal: First successful treatment of epidermolytic Ichthyosis with Vunakizumab: A Case Report. (Pubmed Central) - Jun 2, 2025
After a three-month treatment with Vunakizumab, symptoms alleviated significantly and inflammatory factor levels normalized. This not only shows the great potential of Vunakizumab in treating ichthyosis but also paves the way for further research on anti-IL-17A therapies for skin cornification disorders, offering treatment options for ichthyosis patients.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New trial, Platinum sensitive: A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor (clinicaltrials.gov) - Jun 2, 2025
P=N/A, N=70, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Induction Camrelizumab and Modified TPF (Nab-Paclitaxel, Cisplatin, and S-1) in Locoregionally Advanced Nasopharyngeal Carcinoma. (Pubmed Central) - Jun 1, 2025
Our study suggests that induction chemo-immunotherapy of camrelizumab plus modified TPF demonstrated an excellent CR rate and an acceptable safety profile in patients with LANPC. Trial Registration: ChiCTR240008603.
- |||||||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
New P3 trial: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy (clinicaltrials.gov) - May 30, 2025
P3, N=140, Not yet recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
- | Journal: Successful treatment of an elderly patient with relapsed/refractory angioimmunoblastic T-cell lymphoma with the PI3K? inhibitor linperlisib: a Case Report. (Pubmed Central) - May 30, 2025
inhibitor, combined with gemcitabine/oxaliplatin induced sustained partial remission, followed by linperlisib maintenance...This case highlights the dual role of linperlisib as an effective and well-tolerated therapy for elderly R/R AITL patients who have exhausted prior lines. By precisely targeting PI3K?, our findings offer critical real-world evidence to address the unmet need for safe salvage strategies in this vulnerable population.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma, remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Journal: The ED50 and ED95 of remimazolam tosilate to inhibit the gastroscopy reaction in elderly patients of varying ages: an up-and-down sequential allocation trial. (Pubmed Central) - May 30, 2025
P4
The ED95 estimated by probit regression analysis was 0.199 (95% CI, 0.186-0.244) mg/kg in Group A and 0.188 (95% CI, 0.175-0.232) mg/kg in Group B. RT is a relatively safe sedative hypnotic that can provide a suitable sedative effect for elderly patients undergoing a gastroscopy. http://www.chictr.org.cn, identifier ChiCTR2200062842.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma (clinicaltrials.gov) - May 30, 2025
P2, N=35, Recruiting, Sponsor: Hospital of Stomatology, Wuhan University
http://www.chictr.org.cn, identifier ChiCTR2200062842. Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025
- | Journal: Rechallenge of anti-PD-1 antibody combined with chemotherapy shows promising efficacy in the treatment of advanced metastatic hepatocellular carcinoma: A case report. (Pubmed Central) - May 29, 2025
The patient has been receiving Tislelizumab combined with Xelox for 23 months and has maintained a complete response to treatment. This case indicates that combining immune rechallenge with chemotherapy is beneficial for metastatic hepatocellular carcinoma.
- vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
EFFICACY AND SAFETY OF VUNAKIZUMAB ON ENTHESITIS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: A POST-HOC ANALYSIS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 2/3 STUDY () - May 28, 2025 - Abstract #EULAR2025EULAR_4189;
This post-hoc analysis showed that vunakizumab 120 mg significantly improved enthesitis, as measured by the MASES score, in comparison to placebo at week 16 in patients with active AS. Furthermore, subsequent switching from placebo to vunakizumab also resulted in considerable improvement in enthesitis in this population.
- vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
EFFECT OF VUNAKIZUMAB ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 2/3 STUDY () - May 28, 2025 - Abstract #EULAR2025EULAR_4173;
P2/3
Furthermore, subsequent switching from placebo to vunakizumab also resulted in considerable improvement in enthesitis in this population. Treatment with vunakizumab provides significant and sustained improvements in patient-reported disease activity, functional impairment, health-related quality of life, and pain in patients with active ankylosing spondylitis.
- vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
EFFICACY AND SAFETY OF VUNAKIZUMAB IN ANKYLOSING SPONDYLITIS: A SUBGROUP ANALYSIS BY GENDER () - May 28, 2025 - Abstract #EULAR2025EULAR_4126;
P2/3
The safety profile was manageable and tolerable. These findings highlight the potential of vunakizumab as an effective treatment option for AS patients, regardless of gender.
- ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
EFFICACY OF IVARMACITINIB IN BIOLOGICAL DMARDS-NA () - May 28, 2025 - Abstract #EULAR2025EULAR_3953;
P3
These findings highlight the potential of vunakizumab as an effective treatment option for AS patients, regardless of gender. Ivarmacitinib effectively reduces disease activity and improves health-related quality of life in bDMARDs-na
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Opdivo (nivolumab) / Ono Pharmaceutical, BMS, AiRuiKa (camrelizumab) / Elevar Therapeutics
New trial: PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety (clinicaltrials.gov) - May 28, 2025
P=N/A, N=80, Completed, Sponsor: Jiangxi Provincial Cancer Hospital
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, loperamide / Generic mfg.
PK/PD data, Journal: Evaluation of the pharmacokinetic interactions of montmorillonite powder or loperamide on pyrotinib in healthy volunteers. (Pubmed Central) - May 28, 2025
P1
Based on these findings, loperamide is recommended for symptom control, while montmorillonite powder should not be co-administered with pyrotinib or any drug requiring optimal absorption. [ClinicalTrials.gov], identifier [NCT05252546].
- |||| HRS-7058 / Jiangsu Hengrui Pharma
Enrollment open: A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour (clinicaltrials.gov) - May 28, 2025
P2, N=300, Recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
[ClinicalTrials.gov], identifier [NCT05252546]. Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open: PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov) - May 28, 2025
P2, N=40, Recruiting, Sponsor: Nanfang Hospital, Southern Medical University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| HRS-5965 / Jiangsu Hengrui Pharma
Enrollment change: HRS-5965-203: Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria (clinicaltrials.gov) - May 28, 2025
P2, N=120, Recruiting, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
Not yet recruiting --> Recruiting N=24 --> 120
- ||| SHR-1703 / Jiangsu Hengrui Pharma
Trial completion, Trial primary completion date: A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype (clinicaltrials.gov) - May 28, 2025
P2, N=85, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=24 --> 120 Active, not recruiting --> Completed | Trial primary completion date: Dec 2023 --> Sep 2024
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
New trial: A Study on the Efficacy and Safety of IPyC for HER2+ MBC (clinicaltrials.gov) - May 27, 2025
P=N/A, N=301, Completed, Sponsor: Fujian Medical University
- | Erbitux (cetuximab) / Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date: Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients (clinicaltrials.gov) - May 27, 2025
P2, N=40, Recruiting, Sponsor: Fudan University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2023 --> Sep 2024 Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Avastin (bevacizumab) / Roche
New P1/2 trial, Platinum sensitive: SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - May 27, 2025
P1/2, N=90, Not yet recruiting, Sponsor: Tongji Hospital
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P3 trial, Platinum resistant: SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov) - May 27, 2025
P3, N=300, Not yet recruiting, Sponsor: Tongji Hospital
- | AiTan (rivoceranib) / HLB Bio Group, LY294002 / Eli Lilly
Journal: Cinobufagin inhibits hepatocellular carcinoma EMT-like stemness via VEGF/VEGFR2 autocrine signaling. (Pubmed Central) - May 26, 2025
Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Dec 2024 --> Jun 2025 Cinobufagin may attenuate the PI3K/AKT-dependent metastatic potential of hepatocellular carcinoma by inhibiting the VEGFa/VEGFR2 autocrine pathway.
- | carboplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group, albumin-bound paclitaxel / Generic mfg.
Journal: Immunotherapy combined with chemotherapy: a promising therapeutic approach in the management of colonic squamous cell carcinoma-a case report. (Pubmed Central) - May 26, 2025
The combination therapy resulted in a partial response. This case highlights the potential efficacy of Anti-PD-1 therapy combined with chemotherapy in CSCC, suggesting a possible treatment approach for this rare cancer subtype.
- || Review, Journal: The Importance of Timing in Immunotherapy: A Systematic Review. (Pubmed Central) - May 26, 2025
These results suggest that the timing of immunotherapy administration may significantly impact treatment efficacy, potentially due to interactions with circadian rhythms. Further research is needed to establish standardized guidelines for optimizing infusion timing to enhance patient outcomes.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: Pyrotinib Plus Taxanes or Vinorelbine for the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Prospective Evaluation of Efficacy and Safety. (Pubmed Central) - May 23, 2025
P4
Pyrotinib plus taxanes could be an alternative or even the preferred treatment strategy for patients with HER2-positive MBC after trastuzumab and small-molecule tyrosine kinase inhibitors (TKIs). We also suggest that pyrotinib combined with vinorelbine has a therapeutic potential.
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov) - May 23, 2025
P2, N=88, Recruiting, Sponsor: Fudan University
We also suggest that pyrotinib combined with vinorelbine has a therapeutic potential. Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2025
- || trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
P2 data, Journal: Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial. (Pubmed Central) - May 22, 2025
P2
This is the first study to report the efficacy and safety of third-generation HER2-directed ADC in the neoadjuvant setting for HER2-positive breast cancer. SHR-A1811 showed robust activity, with a tolerable safety profile.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ (clinicaltrials.gov) - May 22, 2025
P2, N=30, Recruiting, Sponsor: Jiangsu Cancer Institute & Hospital
- ||| Preclinical, Review, Journal, Adverse events: T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: preclinical evaluation and mechanisms, prediction, and exploration of adverse effects. (Pubmed Central) - May 22, 2025
Nevertheless, limited research exists regarding the adverse effects and mechanisms of T-DM1 in combination with radiotherapy. This review investigates preclinical studies on the interactions between T-DM1 and radiotherapy, investigates associated adverse effects and their underlying mechanisms, identifies predictive factors and prognostic implications, and explores potential therapeutic strategies involving the concurrent T-DM1 with radiotherapy.
- | Journal, PD(L)-1 Biomarker, IO biomarker: SMARCA4-deficient undifferentiated thoracic tumor: a case report and literature review. (Pubmed Central) - May 22, 2025
This may represent a novel treatment option for this group of patients. Prospective studies will be required to validate the efficacy and safety of this therapy.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Journal: Association between reactive cutaneous capillary endothelial proliferation and the efficacy of camrelizumab in esophageal cancer: a retrospective cohort study. (Pubmed Central) - May 22, 2025
The emergence of RCCEP may serve as a potential predictor for the therapeutic efficacy of camrelizumab in the treatment of EC. More camrelizumab treatment cycles and not receiving combined anti-angiogenic therapy were independent risk factors for RCCEP.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: In Silico Design and Evaluation of Novel Peptide-Based PET Probe for Noninvasive Imaging of HER2 Expression in Breast Cancer. (Pubmed Central) - May 22, 2025
Notably, this radiotracer was successfully utilized to achieve direct visualization of tumor response to pyrotinib, a HER2 tyrosine kinase inhibitor. These findings suggest that the peptide-based radiotracer [68Ga]Ga-DOTA-WC8 represents a promising tool for accurately monitoring of HER2 expression after treatment with HER2-targeting drugs.
- ||| ribupatide oral (HRS9531 tablet) / Kailera Therapeutics
Trial completion: A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects (clinicaltrials.gov) - May 21, 2025
P1, N=72, Completed, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
These findings suggest that the peptide-based radiotracer [68Ga]Ga-DOTA-WC8 represents a promising tool for accurately monitoring of HER2 expression after treatment with HER2-targeting drugs. Recruiting --> Completed
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: Exploring the full potential of Pyrotinib in HER2-positive metastatic breast cancer. (Pubmed Central) - May 21, 2025
Recruiting --> Completed No abstract available
- | oxaliplatin / Generic mfg., capecitabine / Generic mfg.
Trial completion: T+I+XELOX: Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC (clinicaltrials.gov) - May 20, 2025
P=N/A, N=68, Completed, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
No abstract available Active, not recruiting --> Completed